Blog
RSS FeedPosted by Michael Wonder on 29 Jan 2019
Health Canada grants market authorisation for Kalydeco (ivacaftor) in children ages 12 to <24 months with certain mutations in the CFTR gene
28 January 2019 - Kalydeco is the first and only approved medicine in Canada to treat the underlying cause of ...